306
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals – a Danish register-based study of a region with 580,000 citizens

ORCID Icon, ORCID Icon, , , , , , , , & show all
Pages 477-482 | Received 07 Sep 2022, Accepted 30 Oct 2022, Published online: 10 Nov 2022

References

  • Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313–321.e2.
  • Harbord M, Eliakim R, Bettenworth D, European Crohn’s and Colitis Organisation [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
  • Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
  • Alulis S, Vadstrup K, Borsi A, et al. Treatment patterns for biologics in ulcerative colitis and Crohn’s disease: a Danish nationwide register study from 2003 to 2015. Scand J Gastroenterol. 2020;55(3):265–271.
  • Wong DJ, Roth EM, Feuerstein JD, et al. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7(2):77–90.
  • Perera S, Yang S, Stott-Miller M, et al. Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn’s disease. J Health Econ Outcomes Res. 2018;6(1):96–112.
  • Larsen L, Drewes AM, Broberg MCH, et al. Changing infliximab prescription patterns in inflammatory bowel disease: a population-based cohort study, 1999–2014. Inflamm Bowel Dis. 2018;24(2):433–439.
  • Nguyen GC, Laveist TA, Gearhart S, et al. Racial and geographic variations in colectomy rates among hospitalized ulcerative colitis patients. Clin Gastroenterol Hepatol. 2006;4(12):1507–1513.
  • Rencz F, Péntek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in central and eastern Europe. World J Gastroenterol. 2015;21(6):1728–1737.
  • Raine T, Gkini MA, Irving PM, et al. Maintaining clinical freedom whilst achieving value in biologics prescribing: an integrated cross-specialty consensus of UK dermatologists, rheumatologists and gastroenterologists. BioDrugs. 2021;35(2):187–199.
  • STATACorp. Stata Statistical Software.
  • Fonager K, Sørensen HT, Rasmussen SN, et al. Assessment of the diagnoses of Crohn’s disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol. 1996;31(2):154–159.
  • Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
  • Meijer M, Röhl J, Bloomfield K, et al. Do neighborhoods affect individual mortality? A systematic review and meta-analysis of multilevel studies. Soc Sci Med. 2012;74(8):1204–1212.
  • Diderichsen F. Ulighed i Sundhed 2012.
  • Berg DR, Colombel J-F, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(12):1896–1905.
  • Danish National Guidelines. https://www.dsgh.dk/index.php/ibd/biologisk-terapi-behandling

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.